Table 1.
Characteristics of 151 HIV-infected children with available lipid measurements before starting treatment (pre-treatment) with ritonavir-boosted lopinavir (LPV/r)-based therapy and at the time of randomization after achieving virologic suppression (suppressed) on this regimen.
| Pre-treatment (Time 0) | Suppressed (Time 0R) | p-value* | |||
|---|---|---|---|---|---|
| Sex | |||||
| Male | 78 | (51.7) | 78 | (51.7) | |
| Female | 73 | (48.3) | 73 | (48.3) | |
|
| |||||
| Age in months | |||||
| <6 | 41 | (27.2) | - | - | |
| 6 to 11 | 58 | (38.4) | 12 | (8.0) | |
| 12 to 17 | 33 | (21.9) | 60 | (39.7) | |
| 18 to 23 | 19 | (12.6) | 39 | (25.8) | |
| ≥24 | - | - | 40 | (26.5) | |
|
| |||||
| Median age in months | 9.3 | 18.5 | |||
| Range | 2.2-24 | 9.1-35.5 | |||
|
| |||||
| CD4 percent | |||||
| Median | 19.5 | 29.8 | <0.0001 | ||
| Range | 2.6-41.8 | 7.3-55.7 | |||
|
| |||||
| CD4 count cells/mm3 | |||||
| Median | 936 | 1869 | <0.0001 | ||
| Range | 10-3762 | 104-5423 | |||
|
| |||||
| HIV RNA copies per ml † | |||||
| <50 | - | - | 107 | (70.9) | |
| 50-399 | - | - | 44 | (29.1) | |
| 400-99,999 | 13 | (9.0) | - | ||
| 100,000-749,999 | 46 | (31.7) | - | ||
| ≥750 000 | 86 | (59.3) | - | ||
|
| |||||
| Weight for age Z-score | |||||
| Mean [std] | −2.07 [1.65] | −0.54 [1.12] | <0.0001 | ||
|
| |||||
| Height for age Z-score | |||||
| Mean [std] | −3.17 [1.63] | −3.04 [1.55] | >0.10 | ||
*
Paired t-tests were used to compare appropriate parameters pre- and post-treatment
†
Pre-treatment measurements missing for 6 children